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Abstract: 
We have sequenced 463 presenting cases of myeloma entered into the UK Myeloma 
XI study using whole exome sequencing plus capture of the Ig heavy and light chain 
loci together with the region on 8q24 surrounding MYC.  We identify frequent (19%) 
translocation into MYC which together with copy number gain and loss increases the 
prevalence of MYC abnormalities to 57.5%.  MYC translocations are positively 
associated with the hyperdiploid subgroup and poor clinical outcome.  In addition to 
these adverse prognostic translocations we identify mutations induced as a 
consequence of misdirected AID in the partner oncogenes of IGH translocations, 
which are activating and associated with impaired clinical outcome.  An APOBEC 
mutational signature is seen in 3.8% of cases and is linked to the translocation 
mediated deregulation of MAF and MAFB, a known poor prognostic factor.  
Kataegis, a further mutational pattern associated with APOBEC deregulation, is seen 
at the sites of the MYC translocation both at 8q24 and the translocated partner 
chromosome.  The APOBEC mutational signature seen in myeloma is, therefore, 
associated with poor prognosis primary and secondary translocations and the 
molecular mechanisms involved in generating it are potential therapeutic targets.
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Humans have evolved with the need to evade infection and as a consequence have 
developed DNA rearranging mechanisms to generate high affinity antibodies.  An 
inevitable consequence of these processes is the generation of abnormal 
recombination events leading to oncogene activation or tumour suppressor gene 
inactivation. Myeloma is a malignancy of plasma cells that develops later in life in 
which abnormal rearrangements at the Ig loci have been shown to be important 
initiating events. Consequently, studying the mechanisms underlying the 
development of translocations and their downstream effects can provide major 
insights into the aetiology of the disease1.   
Aberrant chromosomal translocations are seen in ~40% of presenting patients and 
predominantly involve the IGH locus at 14q32 2.  There are five main partners to the 
IGH locus which are 4p, 6q, 11q, 16q and 20q all of which are considered as being 
classical myeloma translocations that are seen in close to 100% of the tumour 
population.  These translocations result in the over-expression of an oncogene on 
the partner chromosome which can be categorised using a translocation/cyclin (TC) 
classification3.  The expression of the partner oncogene has a strong influence on 
the cell, resulting in changes to the genome and in a characteristic clinical behaviour 
of the disease.  For example, the t(4;14) results in over-expression of FGFR3 and 
MMSET (WHSC1)4.  This translocation group is associated with a poor prognosis,5 
which is abrogated to some extent by the use of bortezomib treatment6.  The over-
expression of MMSET, which encodes a histone methyltransferase, results in gene 
specific DNA hypermethylation, which is distinct from the other translocation groups7.  
The t(11;14) results in over-expression of CCND1 and the occurrence of this 
translocation is more likely in individuals carrying the G allele of the cyclin D1 SNP, 
rs9344, which affects its splicing pattern8.  Both the t(4;14) and t(11;14) are relatively 
frequent events (12% and 15%, respectively) with the other three translocations 
occurring less frequently.  The t(6;14) (1%) results in over-expression of CCND3 and 
the t(14;16) (4%) and t(14;20) (1%) result in over-expression of the transcription 
factors MAF and MAFB, respectively3.  The ‘maf’ translocations are associated with 
a poor prognosis9. 
In initial sequencing studies of myeloma it has been noted that the spectrum of 
mutations fall into two groups, one of which is characterised by an APOBEC 
signature10.  This signature comprises of C>T, C>G and C>A mutations in a TpC 
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context and it has also been described in several cancers such as breast, 
pancreatic, CLL, and B cell lymphoma.  This mutational signature comprises only a 
subset of samples, with the rest having a rather generic mutation signature with 
enrichment of C>T transitions at CpG dinucleotides, representing an intrinsic 
mutational process occurring as a result of the spontaneous deamination of 
methylated cytosine to thymine.  Here we have performed whole exome sequencing 
on 463 patients with the addition of the Ig and MYC loci, to capture translocation 
breakpoints, copy number abnormalities and somatic mutations to determine how 
these affect mutation patterns in the plasma cell.   
  
6 
 
Results 
Rearrangements at MYC are the most common translocation in 
presenting myeloma and are associated with a poor outcome 
Whole exome sequencing was performed on 463 presentation patients enrolled into 
the Myeloma XI trial.  In addition to capturing the exome, extra baits were added 
covering the IGH, IGK, IGL and MYC loci in order to determine the breakpoints 
associated with translocations in these genes.  These combined data allow us to 
examine the effect of translocations on the mutational spectra in myeloma. Using a 
combination of targeted capture and expression-based classification we identified 
the five main translocation partners and those surrounding the MYC locus.  
Translocations were detected in 232 (50.1%) patients of which 59 patients (12.7%) 
had a t(4;14), 86 patients (18.6%) a t(11;14), 17 patients (3.7%) a t(14;16), 5 patients 
(1%) a t(6;14) and 4 patients (0.9%) a t(14;20).  The remainder had translocations 
involving 8q24 with 21 (4.5%) patients having both a classical translocation and an 
8q24 translocation and 62 (13.4%) having only an 8q24 translocation (of which 54 
were hyperdiploid (HRD) and 8 were neither HRD nor had a classical translocation).  
Breakpoints are shown in Supplementary Figure 1 and the distribution agrees with 
previously published results11.   
MYC translocations were found in 85 patients (18.4%).  The most common partner 
loci were IGH@ (14 patients), IGL@ (14 patients), FAM46C (8 patients), IGK@ (5 
patients), FOXO3 (5 patients) and BMP6 (3 patients).  Several other genes of 
interest in B cells were identified as partners to MYC including RB1, XBP1, TXNDC5, 
CCND3 and CCND1.   It has been suggested previously that super enhancers 
located at these loci upregulate their partner genes12,13.  We report a significant 
negative correlation of MYC translocations with the t(4;14) (correlation=-0.13, 
BF=2.11) and positive correlation with the hyperdiploid (HRD) group 
(correlation=0.13, BF=1.55).  Based on these results we describe MYC 
translocations as being the most common translocation in myeloma and they are 
associated with impaired clinical outcomes (Figure 1A and B).   
We used copy number data, generated from exome sequencing, to identify 
additional abnormalities surrounding the MYC locus.  There is an abnormality in 257 
of the patients (55%), which can be subdivided into those with a translocation alone 
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(8 patients), those with a translocation and a copy number abnormality (77 patients), 
those with focal or chromosomal gains (143 patients) or deletions (29 patients).  We 
examined the expression of MYC in these samples and found a significant increase 
in expression in samples with a MYC translocation compared to those with no 
abnormality (Figure 1C).  Gains and deletions were not associated with significant 
increases in expression of MYC, although those with a deletion did have a median 
expression similar to those with a translocation (26217 vs. 28815 units) and the lack 
of significance is presumably due to lack of numbers in the deleted group.  We 
looked at the clinical significance of carrying these abnormalities and show that 
carrying any MYC abnormality is associated with a poor prognosis (Figure 1A and 
B). 
 
Kataegis mutation patterns co-localise with MYC translocation 
breakpoints. 
We were also able to detect a mutational signature, kataegis, where regional 
clustering of mutations can be indicative of somatic genomic rearrangements14.  It is 
difficult to detect kataegis using exome sequencing but the tiled regions surrounding 
the IGH, IGK, IGL and MYC loci could be used to detect it.  By creating rainfall plots 
we were able to discern samples with regional hypermutation.  As expected, the Ig 
loci contained clusters of hypermutation, but these were not enriched for C>T or 
C>G mutations within a TpCpH trinucleotide context and as such are not caused by 
kataegis.  We found the hallmarks of kataegis in 15 samples (3.2%), where there 
was enrichment for TpCpH mutations with an inter-mutational distance <1 kb (Figure 
2).  Of these 15, 9 were found in the tiled region surrounding MYC and others were 
detected on chromosomes 1, 10, 11, 16, and 17 (Table 2). Kataegis was co-
localised with copy number abnormalities in 12 of the samples.  Two of the samples 
with kataegis surrounding MYC also had an inter-chromosomal translocation at MYC 
involving either IGK or IGL.  Interestingly, the partner chromosomes also showed 
signs of kataegis e.g. in the t(2;8) kataegis was found at IGK and MYC and in the 
t(8;22) kataegis was found at MYC and IGL (Figure 2).  The pattern of mutations 
clustered around the translocation breakpoint and according to the cancer clonal 
fraction (CCF) were present in all cells, indicating that kataegis most likely occurs at 
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the same time as the translocation.  APOBECs are thought to be involved in the 
generation of kataegis and as such this co-localisation is indicative of APOBEC 
involvement in the generation of MYC breakpoints. 
 
Hypermutation of Translocation Partner Oncogenes 
In agreement with previous studies15 we find that CCND1 is mutated, and this was 
seen in 10 patients, all of whom have a t(11;14) (Supplementary Table 2).  All 
mutations occurred in the first exon of CCND1 and all but one were located outside 
of the cyclin box fold domains. Five patients had multiple mutations and the K50R 
mutation was detected in three samples, the K46N mutation was seen in two 
samples but all of the other mutations we describe were unique.  There was no 
association of mutation in CCND1 with translocation breakpoint, type of breakpoint 
(RAG or switch mediated) or allele of the variant associated with the t(11;14).  
However, there was an association of mutated CCND1 and a poor prognosis when 
compared with non-mutated t(11;14) patients (Overall survival median of 20.2 
months versus not reached, p=0.005; Figure 3C) in the Myeloma XI trial. To 
determine the significance of this result we sequenced the first exon of CCND1 in 
102 t(11;14) samples from the Myeloma IX trial and found mutations in a further 10 
samples (9.8%; Supplementary Figure 3).  There was no effect on survival in the 
Myeloma IX dataset with mutations in CCND1.  We also examined the allelic 
frequency of the variant associated with the t(11;14), rs9344, in the Myeloma XI 
dataset and found that in agreement with our previous observations8 the G allele is 
significantly associated with the translocation (Supplementary Figure 4).  
Given the association of mutated CCND1 in the t(11;14) we examined the other 
translocation groups and their associated partner chromosome oncogenes.  We 
found that FGFR3, MAF and MAFB all had mutations which were restricted to the 
relevant translocation group (16.9% mutated FGFR3 in t(4;14); 12.5% mutated MAF 
in t(14;16); and 25% mutated MAFB in t(14;20); Figure 3A).  There were no 
mutations in CCND3 (in 6 t(6;14) patients) and the mutations in MMSET were not in 
t(4;14) patients.  In contrast to the poor prognosis associated with mutations of 
CCND1 in the t(11;14), no poor prognosis was associated with mutations in FGFR3, 
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MAF or MAFB.  However, the latter two sample sets may be too small to address 
this question adequately.   
The mutated oncogenes were all on the der(14) and most likely reflect somatic 
hypermutation events mediated by AID, an member of the APOBEC family, which 
would normally affect the V(D)J rearrangement upstream of the IGH constant 
regions.  After the translocation event, MMSET is on the der(4) and is, therefore, 
unlikely to be mutated by this mechanism.  As AID is associated with hypermutation 
of the V(D)J and switch regions of the highly expressed IGH locus we examined the 
expression of the translocation partner oncogene between those with or without a 
mutation, but found no significant differences (Supplementary Figure 5). 
The CCF in which the mutation was found differs by translocation group (Figure 3B).  
In the t(11;14) the mutations were founder events, present in all of the cells whereas 
in the t(14;16) and t(14;20) the mutations were in only ~50% of the cells indicating 
they are obtained later than the translocation themselves.  In the t(4;14) the 
mutations in FGFR3 can be either clonal or subclonal indicating that these mutations 
can develop at the same time as the translocation or at a later time point. 
The mutation patterns for each of the der(14) oncogenes differ.  In the t(11;14) 
mutations in CCND1 occur solely at the N-terminal of the protein and do not affect 
the cyclin box fold domains.  In MAF and MAFB the mutations are constrained in the 
basic-leucine zipper domain at the C-terminal of the protein.  The focussed mutation 
profile seen in CCND1, MAF and MAFB are indicative of activating mutations.  The 
mutations in FGFR3 are dispersed through several domains but have also been 
described as mutations that can activate the RAS/MAPK pathway in urothelial 
cancer16.  
APOBEC Mutations are enriched in the ‘maf’ translocation groups 
It has previously been shown that mutations can be described in a specific 
trinucleotide context and that in myeloma there are two signatures that 
predominate10.  We are able to recapitulate these two different signatures, which 
consist of a generic signature comprised of enrichment of C>T transitions in a CpG 
context, Signature A (Figure 4A) and a second signature, Signature B, in which 
there is enrichment for C>G and C>T, especially in a TpCpA context.  Signature B is 
hypothesised to result from aberrant APOBEC activity, where the APOBECs 
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enzymatically modify single-stranded DNA.  AID is a member of the APOBEC family 
and is involved in class-switch recombination and somatic hypermutation in B cells. 
We noted that the t(14;16) and t(14;20) have a statistically significant higher number 
of mutations per sample compared to the other translocation sub-groups (p=1.65 
x10-5), Figure 4B, and that the Signature B (APOBEC) related context of mutations 
in the t(14;16) and t(14;20) was significantly higher than other translocation groups 
(T(C>T)A, p=9.1x10-5;   T(C>T)T, p=0.0014; T(C>G)A, p=0.001; T(C>G)T, 
p=0.0064), Figure 4C.  Collectively, mutations in these trinucleotide contexts 
comprise a mean of 28.7% and 21.3% of mutations in t(14;16) and t(14;20) samples, 
respectively (compared to t(4;14) 6.5%, t(6;14) 6.2%, t(11;14) 5.8%). We examined 
the proportion of each Signature present in the translocation sub-groups and found 
that there is a significant enrichment for Signature B (APOBEC) mutations in the 
t(14;16) and t(14;20) (0.56, p=2x10-16; 0.44, p=8.26x10-11, respectively) compared to 
the t(4;14), t(6;14), t(11;14) and hyperdiploid samples (0.094, 0.096, 0.074, 0.098 
and 0.078, respectively) (Figure 4D). These data indicate that the ‘maf’ translocation 
groups are largely characterised by APOBEC signature mutations and have a higher 
mutation load than the other translocation groups. 
In order to determine if there are some samples in the other translocation groups 
which also have an APOBEC signature we assigned each sample to either Signature 
A or Signature B depending on the proportion of mutation type in each sample.  This 
generated clusters of samples whose mutations are either mostly Signature A 
(cluster A) or Signature B (cluster B), Figure 5A.  Here we find that the t(14;16) and 
t(14;20) cases comprise 66.6% of cluster B but only 1.3% of cluster A.  In line with 
the proportion of ‘maf’ samples in Cluster B the number of mutations in this cluster is 
significantly higher than in Cluster A (mean 295.44 vs. 127.22, p=1.18x10-15; Figure 
5B).  Cluster A is comprised of 445 patients and cluster B 18 patients, indicating that 
Signature B only affects 3.9% of patients.  However, when we performed survival 
analysis of these patient clusters we find that there is a significant effect on overall 
survival (p=0.02; Figure 5C).  Due to the interaction of the translocation, APOBEC 
signature and mutational load it is not possible to delineate whether this effect on 
survival is due to any single one of these markers alone and it remains more likely 
that the impact of three abnormalities is linked. 
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Both the t(14;16) and t(14;20) result in over-expression of a maf transcription factor.  
As these translocation groups are enriched for APOBEC signature mutations we 
sought to determine if there is a link between maf gene expression and APOBEC 
expression.  We examined two well-characterised gene expression datasets from 
myeloma patients (UAMS, GSE4581; MRC Myeloma IX, GSE15695) for 
characteristic expression patterns of APOBEC genes in t(14;16) and t(14;20) groups.  
We found that there is significantly increased expression of APOBEC3A and 
APOBEC3B in t(14;16) and t(14;20) cases in both the UAMS and Myeloma IX 
datasets (Figure 6).  Analysis of ENCODE data indicates a MAFK binding site in the 
promoter of APOBEC3A and APOBEC3B.  Although MAFK is a different class of maf 
transcription factor it shares a binding motif with MAF and MAFB, which could 
explain the over-expression of APOBECs in the t(14;16) samples.  Previously, 
APOBEC3B has been associated with C>T transitions in breast cancer,17,18 and 
given that APOBEC3B is significantly over-expressed in t(14;16) or MAF group 
samples in both datasets this is the most likely causative candidate for the C>T 
transitions observed in our Signature B cases.  
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Discussion 
Translocations involving the Ig loci in myeloma are recognised as primary events, 
being present in all cells, whereas copy number abnormalities and somatic mutations 
tend to be present in sub-clones19,20.  Here we identify translocations involving MYC 
as being the most common structural chromosomal abnormalities in myeloma, 
bringing the total translocated group to 50.1% of presenting patients and in addition 
MYC translocations are associated with adverse clinical outcomes.  Furthermore, we 
show that when copy number abnormalities are taken into account, the percentage 
of myeloma cases where MYC is deregulated is 55%, making it the most common 
genetic event in myeloma, being even more common than mutational activation of 
the RAS pathway.  This observation on presenting clinical cases is consistent with 
previous work using myeloma cell lines which suggested that MYC deregulation is 
more or less ubiquitous and is mediated by non-physiological DNA damage and 
repair pathways13. In contrast, we show that in clinical samples the MYC 
translocation partner is an Ig locus in 30% of cases and in the remainder it is 
mediated by translocations to genes expressed at this stage of B cell differentiation.   
While we were able to demonstrate frequent copy number change at the MYC locus, 
using exome sequencing we were unable to gain additional mechanistic information 
as to why these events were occurring.  From both a clinical and aetiological 
standpoint the positive association of MYC translocations with HRD is important 
because it not only reduces the size of the group where HRD is the primary 
aetiological factor but it also removes poor prognostic cases from this group.  
Tiling of the MYC locus enabled us to identify of a second mutational signature, 
kataegis.  This signature is distinct from the APOBEC signature and results in closely 
spaced mutations often surrounding DNA damage breakpoints.  We identified two 
samples with the kataegis signature which also had MYC translocations and in these 
cases the kataegis signature was present on both partner chromosomes, indicating 
that the mutational signature and the translocation co-occurred.  The mechanism 
resulting in kataegis is not known but may also be related to the APOBECs14.  The 
presence of kataegis in the MYC region is of interest because it suggests a 
relationship between it and the development of translocations and copy number 
abnormalities at this site.    
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As initiating events, translocations are poised to control the fate of the cell and 
ultimately of the patient, and as such it is not surprising to find that they drive the 
mutational pathogenesis of the disease. We find that the translocation partner 
oncogene is mutated in 11-25% of samples, depending on the translocation.  We 
show that MMSET is not mutated following translocation in the t(4;14), presumably 
because the site of the breakpoint results in this gene being carried on the der(4) 
chromosome and not the der(14) as is the case with FGFR3, CCND1, MAF and 
MAFB.  There is no specific sequence context within which the mutations on the 
partner oncogenes occur and so they are most likely mediated via aberrant somatic 
hypermutation as a consequence of AID, which would normally mutate the functional 
V(D)J rearrangement on chromosome 14. AID is a member of the APOBEC family 
that deaminates C to U in actively transcribed immunoglobulin variable and switch 
regions resulting in somatic hypermutation.  It is not clear why only a proportion of 
the translocation partner genes are mutated.  However, a similar situation is seen in 
mantle cell lymphoma (MCL) which also harbours a t(11;14).  In this B cell 
malignancy, mutation of CCND1 is also detected in a subset (35%) of cases and is 
associated with SOX11-negative and IGHV-mutated MCL, suggesting their 
acquisition in the germinal centre21.  These mutations are also restricted to the first 
exon of CCND1, consistent with them developing as a consequence of a similar 
mechanism as that seen in myeloma. Interestingly, in terms of the timing of 
development, the mutations are clonal in t(11;14) and in some t(4;14) myeloma 
samples, but are sub-clonal in t(14;16) and t(14;20), indicating that they were 
acquired subsequent to the translocation. 
If the mutations in the partner oncogenes are mediated by AID it raises the question 
as to whether they are simple passenger variants or whether they are driver events 
providing a selection advantage.  Importantly the mutations are not randomly 
distributed within the partner oncogenes.  In CCND1 they are restricted to the 5’ end 
of the gene, outside the cyclin domain.  In MAF and MAFB the mutations are only 
seen in the basic-leucine zipper domain whereas in FGFR3 they are scattered 
throughout the gene.  Interestingly in terms of their pathological relevance although 
the mutations in FGFR3 look random there is evidence that these are involved in 
activation of FGFR3 and downstream signalling of the RAS/MAPK pathway16.  Many 
of the mutations in FGFR3 result in acquisition of a cysteine residue, often involved 
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in di-sulphide bond formation, which may result in homo-dimerization and activation 
of the molecule.  Mutations in FGFR3 also included the K650 mutation, which 
constitutively activates the receptor22. We conclude, therefore, that these mutations 
have been positively selected for their importance in the pathogenesis of the disease 
and could be targeted therapeutically. 
Mutations in cancer samples can be sub-divided based on the context of the 
surrounding bases.  Two signatures have previously been identified in myeloma, the 
second of which is an APOBEC signature, and here we have been able to identify a 
specific genomic subgroup affected by this signature.  APOBECs are a family of 
DNA editing enzymes, which mostly act on single-stranded DNA through 
deamination of cytosine to uracil23.  As such, they have a characteristic pattern of 
mutation which results in enrichment from C>G and C>T mutations in a TpCpH 
context.  Here we find this signature in 18 of the 463 samples and these samples are 
highly enriched for the maf translocations, t(14;16) and t(14;20).  These samples in 
turn also have a higher mutation load than the other samples and the samples with 
this signature have an adverse progression free (PFS) and overall survival (OS).  
While the t(14;16) and t(14;20) have been shown to be adverse prognostic 
previously,24-26 the mechanism by which this is mediated has been unclear.  It is 
known that the t(14;16) and t(14;20) as well as the t(4;14) result in the indirect 
upregulation of CCND23 but the relationship of this to adverse outcomes is 
undetermined.  Here, we show that the t(14;16) and the t(14;20) have more 
mutations than other cytogenetic groups of myeloma, these mutations have an 
APOBEC signature, and they over-express APOBEC genes, specifically APOBEC3A 
and APOBEC3B.  The common mechanism between the two different translocation 
groups is that they result in over-expression of a maf transcription factor (MAF or 
MAFB).  Interestingly, examination of ENCODE data shows maf binding sites in the 
promoter regions of APOBEC3A and APOBEC3B, giving a link between the 
translocations and the increase in mutation load and type.  APOBEC3B has also 
been implicated in the APOBEC mutational signature in breast, ovarian and multiple 
other human cancers, consistent with these data17,18,27. 
It is interesting to note that the presence of t(14;16) or t(14;20) in pre-malignant 
MGUS and asymptomatic myeloma is associated with a favourable prognosis and a 
long time to progression to myeloma in contrast to when they are seen in myeloma9.  
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Given their high mutational burden of this subgroup it will be important to determine if 
the mutational signature seen in the maf sub-groups is also present at the MGUS 
stage or whether the signature only manifests when the disease has progressed to 
myeloma. 
Here we show three different mutational signatures mediated by the APOBEC family: 
translocation partner mutation by AID, Signature B (APOBEC) mediated by 
APOBEC3A or APOBEC3B, and kataegis mediated by an unknown APOBEC family 
member.  We also show for the first time a clinical impact of APOBEC mutations and 
their association with a poor prognosis.  The poor prognosis of this mutational 
signature is inextricably linked to a high mutation load and the adverse t(14;16) and 
t(14;20) translocation subgroups, making it not currently possible to disentangle the 
individual impact of these markers on prognosis.  
Methods 
Methods and any associated references are available in the online version of the 
paper. 
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Tables 
Table 1: Patient Demographics 
Variable n=463 
Median age (range) 68 (31-89) 
Sex ratio (M:F) 1.4:1 
Pathway 
Intensive 
Non-intensive 
 
262 (57%) 
201 (43%) 
Isotype 
IgA 
IgD 
IgG 
Light chain only 
Non-Secretors 
Data missing 
 
121 (26%) 
8 (1.7%) 
263 (57%) 
55 (12%) 
2 (1%) 
14 (3%) 
ISS stage 
I 
II 
III 
II+III 
Data missing 
 
140 (30%) 
135 (29%) 
159 (34%) 
294 (63%) 
29 (6%) 
Beta-2-microglobulin 
 3.5 mg/L 
3.5<-<5.5 mg/L 
5.5 mg/L 
Data missing 
 
153 (33%) 
119 (26%) 
162 (35%) 
29 (6%) 
Creatinine 
 104 µmol/L 
 150 µmol/L 
 
162 (35%) 
57 (13%) 
Bone disease 324 (70%) 
Hypercalcaemia  2.65 mmol/L 58 (12.5%) 
Copy number abnormality (gene) 
del(1p33) (FAF1/CDNK2C) 
del(1p12) (FAM46C) 
gain(1q21.2) (CKS1B) 
del(13q) (RB1) 
del(17p) (TP53) 
Hyperdiploidy 
 
39 (8.5%) 
111 (24%) 
166 (36%) 
195 (42%) 
44 (9.5%) 
239 (52%) 
Translocations 
t(4;14) 
t(6;14) 
t(11;14) 
t(14;16) 
t(14;20) 
 
59 (12.7%) 
5 (1%) 
86 (18.6%) 
17 (4%) 
4 (1%)
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Figure Legends 
Figure 1: MYC abnormalities affect survival. A, Progression free survival.  B, 
Overall survival. C, MYC expression in different abnormality groups. 
 
Figure 2: Kataegis in myeloma.  Kataegis at 8q24 coincides with translocation 
breakpoints and occurs on both chromosomes where a translocation has occurred.  
Examples of two samples are shown.  For each sample the top left plot shows the 
distances between mutations and are colored on a chromosomal basis according to 
UCSC coloring.  The top right panel show the same data but is colored by mutation 
type, as per the key.  The bottom panels show the location on chromosome 8 and 
the partner translocation chromosome (22 or 2, respectively) where kataegis is found 
with genes or Ig loci segments indicated in green or cyan, respectively.  The arrows 
indicated the position of the translocation breakpoint. 
 
Figure 3: Mutations in translocation partner oncogenes.  (A) Non-synonymous 
mutations in translocation partner oncogenes are depicted along with the 
translocation group they occur in.  (B) The cancer cell fraction (CCF) in which the 
mutations occur. (C) Mutation of CCND1 in t(11;14) samples results in decreased 
overall survival in Myeloma XI samples. 
 
Figure 4: Analysis of mutation context identifies two signatures in myeloma. 
(A) Mutation context identifies two signatures in myeloma, Signature A and Signature 
B.  (B) t(14;16) and t(14;20) samples have significantly more mutations than other 
translocation groups. (C) The mutational context split by translocation group 
identifies t(14;16) and t(14;20) with more mutations which make up Signature B. (D) 
Stacked bar chart showing the percentage contribution of the two signatures 
identified by NMF in each sample, ordered by translocation group. 
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Figure 5:  Myeloma mutations can be categorised as belonging to Signature A 
or Signature B.  (A) Samples which mostly have Signature B mutations dominate 
Cluster B and are enriched for t(14;16) and t(14;20). (B) Samples in Cluster B have 
more mutations than those in Cluster A.  Patients in Cluster B have a significantly 
worse overall survival (C). 
 
Figure 6: t(14;16)/MAF samples have increased expression of APOBEC genes 
in the Myeloma IX (GSE15695) and the UAMS datasets (GES4581).  APOBEC3A 
(210873_x_at) and APOBEC3B (206632_s_at) were tested for increased expression 
in the t(14;16)/MAF samples and the significant results shown. 
  
19 
 
References 
1. Morgan, G.J., Walker, B.A. & Davies, F.E. The genetic architecture of multiple 
myeloma. Nat Rev Cancer 12, 335-48 (2012). 
2. Kuehl, W.M. & Bergsagel, P.L. Multiple myeloma: evolving genetic events and 
host interactions. Nat.Rev.Cancer 2, 175-187 (2002). 
3. Zhan, F. et al. The molecular classification of multiple myeloma. Blood 108, 
2020-8 (2006). 
4. Chesi, M. et al. The t(4;14) translocation in myeloma dysregulates both 
FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid 
transcripts. Blood 92, 3025-3034 (1998). 
5. Walker, B.A. et al. A compendium of myeloma-associated chromosomal copy 
number abnormalities and their prognostic value. Blood 116, e56-65 (2010). 
6. Pineda-Roman, M. et al. Sustained complete remissions in multiple myeloma 
linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J 
Haematol 140, 625-34 (2008). 
7. Walker, B.A. et al. Aberrant global methylation patterns affect the molecular 
pathogenesis and prognosis of multiple myeloma. Blood 117, 553-62 (2011). 
8. Weinhold, N. et al. The CCND1 c.870G>A polymorphism is a risk factor for 
t(11;14)(q13;q32) multiple myeloma. Nat Genet 45, 522-5 (2013). 
9. Ross, F.M. et al. The t(14;20) is a poor prognostic factor in myeloma but is 
associated with long-term stable disease in monoclonal gammopathies of 
undetermined significance. Haematologica 95, 1221-5 (2010). 
10. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. 
Nature 500, 415-21 (2013). 
11. Walker, B.A. et al. Characterization of IGH locus breakpoints in multiple 
myeloma indicates a subset of translocations appear to occur in pregerminal 
center B cells. Blood 121, 3413-9 (2013). 
12. Walker, B.A. et al. Translocations at 8q24 juxtapose MYC with genes that 
harbor superenhancers resulting in overexpression and poor prognosis in 
myeloma patients. Blood Cancer J 4, e191 (2014). 
13. Affer, M. et al. Promiscuous MYC locus rearrangements hijack enhancers but 
mostly super-enhancers to dysregulate MYC expression in multiple myeloma. 
Leukemia (2014). 
14. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast 
cancers. Cell 149, 979-93 (2012). 
15. Chapman, M.A. et al. Initial genome sequencing and analysis of multiple 
myeloma. Nature 471, 467-72 (2011). 
16. Foth, M. et al. Fibroblast growth factor receptor 3 activation plays a causative 
role in urothelial cancer pathogenesis in cooperation with Pten loss in mice. J 
Pathol (2014). 
17. Burns, M.B. et al. APOBEC3B is an enzymatic source of mutation in breast 
cancer. Nature 494, 366-70 (2013). 
18. Burns, M.B., Temiz, N.A. & Harris, R.S. Evidence for APOBEC3B 
mutagenesis in multiple human cancers. Nat Genet 45, 977-83 (2013). 
19. Melchor, L. et al. Single-cell genetic analysis reveals the composition of 
initiating clones and phylogenetic patterns of branching and parallel evolution 
in myeloma. Leukemia (2014). 
20 
 
20. Gabrea, A., Leif Bergsagel, P. & Michael Kuehl, W. Distinguishing primary 
and secondary translocations in multiple myeloma. DNA Repair (Amst) 5, 
1225-33 (2006). 
21. Bea, S. et al. Landscape of somatic mutations and clonal evolution in mantle 
cell lymphoma. Proc Natl Acad Sci U S A 110, 18250-5 (2013). 
22. Bellus, G.A. et al. Distinct missense mutations of the FGFR3 lys650 codon 
modulate receptor kinase activation and the severity of the skeletal dysplasia 
phenotype. Am J Hum Genet 67, 1411-21 (2000). 
23. Bacolla, A., Cooper, D.N. & Vasquez, K.M. Mechanisms of base substitution 
mutagenesis in cancer genomes. Genes (Basel) 5, 108-46 (2014). 
24. Boyd, K.D. et al. A novel prognostic model in myeloma based on co-
segregating adverse FISH lesions and the ISS: analysis of patients treated in 
the MRC Myeloma IX trial. Leukemia 26, 349-55 (2012). 
25. Avet-Loiseau, H. Ultra high-risk myeloma. Hematology Am Soc Hematol Educ 
Program 2010, 489-93 (2010). 
26. Mateos, M.V. et al. Bortezomib, melphalan, and prednisone versus 
bortezomib, thalidomide, and prednisone as induction therapy followed by 
maintenance treatment with bortezomib and thalidomide versus bortezomib 
and prednisone in elderly patients with untreated multiple myeloma: a 
randomised trial. Lancet Oncol 11, 934-41 (2010). 
27. Leonard, B. et al. APOBEC3B upregulation and genomic mutation patterns in 
serous ovarian carcinoma. Cancer Res 73, 7222-31 (2013). 
 






